Literature DB >> 9333044

Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam.

T A Kadima1, J H Weiner.   

Abstract

Resistance to piperacillin in several isolates of Citrobacter freundii and Enterobacter cloacae was investigated and confirmed to occur at a frequency of 10(-7) to 10(-6). Development of resistance to piperacillin was significantly suppressed by tazobactam but not by clavulanic acid. To elucidate the mechanism by which resistance suppression occurs, the effect of piperacillin plus tazobactam on the induction of AmpC beta-lactamase was analyzed by monitoring the beta-galactosidase activity of an inducible ampC-lacZ gene fusion in Escherichia coli. The combination exerted no inhibitory effect on AmpC beta-lactamase induction. Tazobactam also had no effect on the accumulation of a key intermediate in the AmpC beta-lactamase induction pathway, 1,6-anhydromurotripeptide, in an ampD mutant strain of E. coli. However, the addition of tazobactam to liquid cultures of E. cloacae 40001 in the presence of piperacillin at four times the MIC caused a delay in the recovery of the culture to piperacillin-induced stress. At 16 times the MIC, a complete suppression of regrowth occurred. Analysis of culture viability on piperacillin plates showed that the culture recovery was due to growth by moderately resistant mutants preexisting in the cell population, which at 16 times the MIC became susceptible to the combination. Evidence from the kinetics of inhibition of the E. cloacae 40001 AmpC beta-lactamase by clavulanic acid, sulbactam, and tazobactam and from the effects of these drugs on the frequency of resistance to piperacillin suggests that the suppressive effect of tazobactam on the appearance of resistance is primarily mediated by the beta-lactamase inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333044      PMCID: PMC164089     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.

Authors:  L Gutmann; M D Kitzis; S Yamabe; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 2.  Contribution of chromosomal beta-lactamases to beta-lactam resistance in enterobacteria.

Authors:  F Lindberg; S Normark
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug

Review 3.  Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future.

Authors:  C C Sanders; W E Sanders
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

4.  The nationwide nosocomial infection rate. A new need for vital statistics.

Authors:  R W Haley; D H Culver; J W White; W M Morgan; T G Emori
Journal:  Am J Epidemiol       Date:  1985-02       Impact factor: 4.897

5.  Development of resistance to cephalosporins in clinical strains of Citrobacter spp.

Authors:  T D Gootz; D B Jackson; J C Sherris
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

6.  Mutational enzymatic resistance of Enterobacter species to beta-lactam antibiotics.

Authors:  M F Lampe; B J Allan; B H Minshew; J C Sherris
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

7.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

8.  Inoculum effect of beta-lactam antibiotics on Enterobacteriaceae.

Authors:  R H Eng; C Cherubin; S M Smith; F Buccini
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

9.  Regulatory components in Citrobacter freundii ampC beta-lactamase induction.

Authors:  F Lindberg; L Westman; S Normark
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

10.  [Effectiveness and tolerance of piperacillin in 333 patients].

Authors:  Y Mouton; C Beuscart; C Soussy
Journal:  Presse Med       Date:  1986-12-20       Impact factor: 1.228

View more
  6 in total

1.  The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase.

Authors:  R A Powers; J Blázquez; G S Weston; M I Morosini; F Baquero; B K Shoichet
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

2.  Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture.

Authors:  Donatella Tondi; Federica Morandi; Richard Bonnet; M Paola Costi; Brian K Shoichet
Journal:  J Am Chem Soc       Date:  2005-04-06       Impact factor: 15.419

3.  Emergence of Resistance in Klebsiella aerogenes to Piperacillin-Tazobactam and Ceftriaxone.

Authors:  Marco M Custodio; Daniel Sanchez; Beverly Anderson; Keenan L Ryan; Carla Walraven; Renee-Claude Mercier
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 4.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.

Authors:  Lorna E T Stearne; Doret van Boxtel; Nicole Lemmens; Wil H F Goessens; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

6.  Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.

Authors:  M Gorschlüter; C Hahn; A Fixson; U Mey; C Ziske; E Molitor; R Horré; T Sauerbruch; G Marklein; I G H Schmidt-Wolf; A Glasmacher
Journal:  Support Care Cancer       Date:  2003-04-11       Impact factor: 3.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.